biostudies-literatureEpps KCNCATS NIH HHSNIA NIH HHSNHLBI NIH HHS100978https://www.ebi.ac.uk/biostudies/studies/S-EPMC10950300biostudies-literatureUnknown2(5)<h4>Background</h4>Little is known about sex-related differences in outcomes of patients with cardiogenic shock (CS) treated within a standardized team-based approach (STBA).<h4>Methods</h4>We evaluated 520 consecutive patients (151 women and 369 men) with CS due to acute myocardial infarction (AMI) and heart failure (HF) in a single-center registry (January 2017-December 2019) and examined outcomes according to sex and CS phenotype. The primary outcome was in-hospital mortality. Secondary outcomes included major adverse cardiac events, 30-day mortality, major bleeding, vascular complications, and stroke.<h4>Results</h4>Women with AMI-CS had higher baseline acuity (CardShock score: female [F]: 5.5 vs male [M]: 4.0; <i>P</i> = .04). Women with HF-CS more often presented with cardiac arrest (F: 12.4% vs M: 2.4%; <i>P</i>< .01) and had higher rates of vasopressor use (F: 70.8% vs M: 58.0%; <i>P</i> = .04) and mechanical circulatory support (F: 46.1% vs M: 32.5%; <i>P</i> = .04). There were no sex-related differences in in-hospital mortality for AMI-CS (F: 45.2% vs M: 36.9%; <i>P</i> = .28) and HF-CS (F: 28.1% vs M: 24.5%; <i>P</i> = .56). Women with HF-CS experienced higher rates of major bleeding (F: 25.8% vs M: 13.7%; <i>P</i> = .02) and vascular complications (F: 15.7% vs M: 6.1%; <i>P</i> = .01). However, female sex was not an independent predictor of these complications. No sex differences in survival were noted at 1 year.<h4>Conclusions</h4>Within an STBA, although women with AMI-CS and HF-CS presented with higher acuity, they experienced similar in-hospital mortality, major adverse cardiac events, 30-day mortality, stroke, and 30-day readmissions as men. Further research is needed to better understand the extent to which historical differences in CS outcomes can be mitigated by an STBA.Journal of the Society for Cardiovascular Angiography & InterventionsSex-Related Differences in Patient Characteristics, Hemodynamics, and Outcomes of Cardiogenic Shock: INOVA-SHOCK Registry.PMC10950300UL1 TR003015R01 HL151293P30 AG021334R01 AG078153R21 AG072095K23 HL153771R01 HL154768Sherwood MWEpps KCPsotka MSinha SSTruesdell AGdeFilippi CRosner CTang DDesai SRaja ABatchelor WTehrani BNDamluji AACotugno AO'Connor CSingh RIbrahim NBagchi PfalseSex-Related Differences in Patient Characteristics, Hemodynamics, and Outcomes of Cardiogenic Shock: INOVA-SHOCK Registry.<h4>Background</h4>Little is known about sex-related differences in outcomes of patients with cardiogenic shock (CS) treated within a standardized team-based approach (STBA).<h4>Methods</h4>We evaluated 520 consecutive patients (151 women and 369 men) with CS due to acute myocardial infarction (AMI) and heart failure (HF) in a single-center registry (January 2017-December 2019) and examined outcomes according to sex and CS phenotype. The primary outcome was in-hospital mortality. Secondary outcomes included major adverse cardiac events, 30-day mortality, major bleeding, vascular complications, and stroke.<h4>Results</h4>Women with AMI-CS had higher baseline acuity (CardShock score: female [F]: 5.5 vs male [M]: 4.0; <i>P</i> = .04). Women with HF-CS more often presented with cardiac arrest (F: 12.4% vs M: 2.4%; <i>P</i>< .01) and had higher rates of vasopressor use (F: 70.8% vs M: 58.0%; <i>P</i> = .04) and mechanical circulatory support (F: 46.1% vs M: 32.5%; <i>P</i> = .04). There were no sex-related differences in in-hospital mortality for AMI-CS (F: 45.2% vs M: 36.9%; <i>P</i> = .28) and HF-CS (F: 28.1% vs M: 24.5%; <i>P</i> = .56). Women with HF-CS experienced higher rates of major bleeding (F: 25.8% vs M: 13.7%; <i>P</i> = .02) and vascular complications (F: 15.7% vs M: 6.1%; <i>P</i> = .01). However, female sex was not an independent predictor of these complications. No sex differences in survival were noted at 1 year.<h4>Conclusions</h4>Within an STBA, although women with AMI-CS and HF-CS presented with higher acuity, they experienced similar in-hospital mortality, major adverse cardiac events, 30-day mortality, stroke, and 30-day readmissions as men. Further research is needed to better understand the extent to which historical differences in CS outcomes can be mitigated by an STBA.2023-01-01T00:00:00Z2023 Sep-Oct2025-04-04T20:07:17.345Z2025-04-04T20:07:17.345ZS-EPMC109503003850477810.1016/j.jscai.2023.100978